NO20015059L - HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter - Google Patents

HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter

Info

Publication number
NO20015059L
NO20015059L NO20015059A NO20015059A NO20015059L NO 20015059 L NO20015059 L NO 20015059L NO 20015059 A NO20015059 A NO 20015059A NO 20015059 A NO20015059 A NO 20015059A NO 20015059 L NO20015059 L NO 20015059L
Authority
NO
Norway
Prior art keywords
antioxidants
association
combination therapy
hcv combination
containing ribavirin
Prior art date
Application number
NO20015059A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015059D0 (no
Inventor
Clifford A Brass
Paul W Glue
Edward Piken
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20015059D0 publication Critical patent/NO20015059D0/no
Publication of NO20015059L publication Critical patent/NO20015059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20015059A 1999-04-19 2001-10-18 HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter NO20015059L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29468799A 1999-04-19 1999-04-19
PCT/US2000/010240 WO2000062799A1 (fr) 1999-04-19 2000-04-18 Polytherapie de l'hepatite c utilisant de la ribavirine associee a des anti-oxydants

Publications (2)

Publication Number Publication Date
NO20015059D0 NO20015059D0 (no) 2001-10-18
NO20015059L true NO20015059L (no) 2001-12-19

Family

ID=23134504

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015059A NO20015059L (no) 1999-04-19 2001-10-18 HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter

Country Status (14)

Country Link
EP (1) EP1046399A1 (fr)
JP (1) JP2002542202A (fr)
CN (1) CN1355708A (fr)
AR (1) AR023541A1 (fr)
AU (1) AU4463300A (fr)
BR (1) BR0009840A (fr)
CA (1) CA2306039A1 (fr)
CO (1) CO5241354A1 (fr)
HU (1) HUP0200942A3 (fr)
MX (1) MXPA00003974A (fr)
NO (1) NO20015059L (fr)
PE (1) PE20010284A1 (fr)
WO (1) WO2000062799A1 (fr)
ZA (1) ZA200108571B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
KR20030005197A (ko) 2000-02-18 2003-01-17 샤이어 바이오켐 인코포레이티드 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법
IL155730A0 (en) 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2003024461A1 (fr) * 2001-09-20 2003-03-27 Schering Corporation Polytherapie de l'hepatite c
US20040022873A1 (en) * 2001-11-09 2004-02-05 Guilford F. Timothy Systemic administration of NAC as an adjunct in the treatment of bioterror exposures such as anthrax, smallpox or radiation and for vaccination prophylaxis, and use in combination with DHEA for the treatment of smallpox and other viruses
DE60311702T2 (de) * 2002-06-03 2007-10-31 National Health Research Institutes Behandlung von Flavivirusinfizierungen
CA2509955A1 (fr) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations utiles pour lutter contre les infections par le virus de l'hepatite c
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2516333C (fr) * 2003-02-21 2011-08-23 Mochida Pharmaceutical Co., Ltd. Medicament destine a attenuer les effets secondaires dans la therapie combinee interferon / ribaverine
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
WO2005120479A1 (fr) * 2004-06-09 2005-12-22 Gpc Biotech Ag Utilisation de selenium ou d'un sel de selenium et d'un acide retinoique ou d'un retinoide pour traiter une hepatite c virale
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (fr) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Système de libération osmotique avec ensemble de piston
WO2008133908A2 (fr) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Formulations en suspension de peptides insulinotropes et leurs utilisations
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CA3007787C (fr) 2010-06-03 2020-03-10 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20130129680A1 (en) * 2011-11-23 2013-05-23 Thomas Christian Lines Method for treating hepatitis c virus infection using quercetin-containing compositions
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Ｔｅｃ家族激酶抑制劑佐劑療法
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5157998A (en) * 1996-11-01 1998-05-29 Thomas Najarian Methods and compositions for treatment of hepatitis c infection

Also Published As

Publication number Publication date
CO5241354A1 (es) 2003-01-31
AR023541A1 (es) 2002-09-04
CA2306039A1 (fr) 2000-10-19
JP2002542202A (ja) 2002-12-10
AU4463300A (en) 2000-11-02
EP1046399A1 (fr) 2000-10-25
ZA200108571B (en) 2003-01-20
NO20015059D0 (no) 2001-10-18
PE20010284A1 (es) 2001-03-05
WO2000062799A1 (fr) 2000-10-26
HUP0200942A3 (en) 2003-03-28
BR0009840A (pt) 2002-01-08
MXPA00003974A (es) 2002-03-08
CN1355708A (zh) 2002-06-26
HUP0200942A2 (hu) 2002-07-29

Similar Documents

Publication Publication Date Title
NO20015059D0 (no) HCV-kombinasjonsterapi, inneholdende ribavirin i assosiasjon med antioksydanter
EE04528B1 (et) Teraapias kasutatavad spirofuropridiinide aralklamiinid
PT1157023E (pt) Epotilonas modificadas em c-21
AR028622A1 (es) Derivados de tropano utiles en terapia
DE69904016D1 (de) Laminatformkörper
EP1545219A4 (fr) Therapie cellulaire de regeneration
DE60022254D1 (de) Verbesserungen in Reifen
DK0903130T4 (da) Forbedringer i forbindelse med ostomiindretninger
FI20010557A0 (fi) Menetelmä vaihtosuuntaajan yhteydessä
DE50015441D1 (de) Fadenliefergerät mit verstellbarer fadenleiteinrichtung
IL165521A0 (en) Interferon-beta in HCV
NO20021976D0 (no) Selektiv leverterapi
DE50009602D1 (de) Absorptionskühlanordnung
IT1310385B1 (it) Dispositivo per migliorare la respirazione.
ITTO20000364A0 (it) Telaio scocca per motociclo.
DE50004514D1 (de) Signalisierungsverfahren im rach-kanal
NO20030214D0 (no) CRF2 ligander i kombinasjonsterapi
DK1065098T3 (da) Arrangement i lastrum
NO991170D0 (no) Anordning i forbindelse med supplementµre tjenester
NO991343L (no) Anordning i forbindelse med supplementære tjenester
TW435091U (en) Underpants with dividing structure
FI990112A0 (fi) Lehmän poikimavahti
BR7902842Y1 (pt) disposiÇço introduzida em quadro de distribuiÇço.
ES1042436Y (es) Posavasos perfeccionado.
ES1044603Y (es) Preservativo perfeccionado.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application